The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
RelevanceLPS is a major component of the cell membrane of Gram negative bacteria, contributing greatly to the structural integrity of the bacteria, and protecting the membrane from certain kinds of chemical attack. LPS is an endotoxin, inducing a strong response from normal animal immune systems. LPS function has been under experimental research for several years due to its role in activating many transcriptional factors, which become active after stimulation with LPS. LPS also induces many types of mediators involved in septic shock.
Chlamydia trachomatis is an intracellular organism. It has a genome size of approximately 500-1000kB and contains both RNA and DNA. Colonization of Chlamydia begins with attachment to sialic acid receptors on the eye, throat or genitalia. It persists at body sites that are inaccessible to phagocytes, T-cells, and B-cells. It also exists as 15 different serotypes. These serotypes cause four major diseases in humans: endemic trachoma (caused by serotypes A and C), sexually transmitted disease and inclusion conjunctivitis (caused by serotypes D and K), and lymphogranuloma venereum (caused by serotypes L1, L2, and L3). Studies reveal that Chlamydia, because of its cell wall, is able to inhibit phagolysosome fusion in phagocytes. The cell wall is proposed to be gram-negative in that it contains an outer lipopolysaccharide (LPS) membrane, but it lacks peptidoglycan in its cell wall.
References for Anti-Chlamydia trachomatis LPS antibody [CL21-335.2.3.] (ab41196)
has not yet been referenced specifically in any publications.
Publishing research using ab41196? Please let us know so that we can cite the reference in this datasheet.
Concentration of lot no. is
Concentration not available for this lot.
Find concentration of your lot:
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"